Pangaea Oncology, S.A. (BME:PANG)

Market Cap	56.74M -4.5%
Revenue (ttm)	16.73M +68.1%
Net Income	-3.60M
EPS	-0.10
Shares Out	35.91M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	8
Open	1.580
Previous Close	1.580
Day's Range	1.580 - 1.580
52-Week Range	1.510 - 1.750
Beta	0.01
Analysts	n/a
Price Target	n/a
Earnings Date	May 12, 2026

About Pangaea Oncology

Pangaea Oncology, S.A., a medical services company, provides a range of services to cancer patients in Spain and the rest of European Union countries. It offers molecular diagnostics, such as mutation analysis in tissue and liquid biopsy, gene amplification and translocation testing, immunohistochemistry and fluorescence in-situ hybridization, and gene expression profiling; clinical trials; in vitro drug profiling, including MTT proliferation assays, western blotting, colony formation, migration and invasion assays, and gene silencing; and Dx p...

• Industry: Diagnostics & Research
• Sector: Healthcare
• Founded: 2006
• Employees: 165
• Stock Exchange: Madrid Stock Exchange
• Ticker Symbol: PANG

Financial Performance

In 2025, Pangaea Oncology's revenue was 16.73 million, a decrease of -0.32% compared to the previous year's 16.79 million. Losses were -3.60 million, 208.3% more than in 2024.